Multi-Objective Optimization of Population-Level Dosing Regimens
Clinical Pharmacokinetics · 12.11.2026
DOI: 10.1007/s40262-026-01714-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 12.11.2026. Verfasst von Sebastian T Tandar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. s.t.tandar@lacdr.leidenuniv.nl. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Longfonds.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Drug treatment optimization involves multiple competing objectives, including efficacy, toxicity, resistance, and cost. It is further complicated by interindividual variability that can make standardized regimens suboptimal for individual patients. We developed a population pharmacokinetics- pharmacodynamics (PKPD)-based framework to optimize dosing regimen at the population-level while accounting for interindividual variability, covariate distributions, and clinical expert input. METHODS: The framework optimizes treatment design parameters, including dose and dosing frequency, to maximize population attainment of treatment objectives. Individual attainment of these objectives is estimated using a population PKPD model and quantified into a penalty metric to enable multi-objective dose regimen optimization. Clinical expert input is incorporated through two approaches: 1) multi-criteria decision analysis (MCDA)-based objective weight assignment and 2) gate optimization, an approach to search for a treatment design for which target attainment is equal to or greater than a reference treatment across all objectives. RESULTS: The framework was evaluated in case studies to highlight how this approach can support complex treatment design, incorporate clinical expert input, and integrate covariate information. Grid search evaluation confirmed that the framework identifies solutions close to the expected location of the global optimum. CONCLUSION: The presented framework is adaptable to diverse patient and disease contexts and supports population-level, model-informed dosing optimization.
Autor:innen und Institutionen
- Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. s.t.tandar@lacdr.leidenuniv.nl.
- Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
- Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. coen.vanhasselt@lacdr.leidenuniv.nl.
Förderung
- Longfonds
Zitieren
APA
Tandar, S. T., Beldjenna, M., Nicholl-Morris, K., van Wijk, R. C., Guo, T., Aulin, L. B. S., & van Hasselt, J. G. C. (2026). Multi-Objective Optimization of Population-Level Dosing Regimens. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01714-5
Vancouver
Tandar ST, Beldjenna M, Nicholl-Morris K, van Wijk RC, Guo T, Aulin LBS, et al. Multi-Objective Optimization of Population-Level Dosing Regimens. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01714-5
BibTeX
@article{Tandar2026,
author = {Tandar, Sebastian T and Beldjenna, Massinissa and Nicholl-Morris, Kieran and van Wijk, Rob C and Guo, Tingjie and Aulin, Linda B S and van Hasselt, J G Coen},
title = {Multi-Objective Optimization of Population-Level Dosing Regimens},
journal = {Clinical Pharmacokinetics},
year = {2026},
doi = {10.1007/s40262-026-01714-5}
}
EUVIMED